Special collections

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Yonglin Hua, Zhixian Sun, Yuxin Xiao, Huilong Li, Xiaowu Ma, Xuan Luo, Wenliang Tan, Zhiqin Xie, Ziyu Zhang, Chenwei Tang, Hongkai Zhuang, Weikai Xu, Haihong Zhu, Yajin Chen, Changzhen Shang

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008953; DOI: 10.1136/jitc-2024-008953
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary study
Gaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, Najeeb Halabi, Eliane Mery-Lamarche, Noemie Thebault, Clara-Maria Scarlata, Marie Michelas, Anne-Sophie Navarro, Gwenaël Ferron, Fabrice Lecuru, Patrice Mathevet, Jonathan Khalifa, Maha Ayyoub, Arash Rafii, Alejandra Martinez

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008734; DOI: 10.1136/jitc-2023-008734
Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment
Yoonjeong Choi, Seong A Kim, Hanul Jung, Eunhae Kim, Yoon Kyoung Kim, Seohyun Kim, Jaehyun Kim, Yeji Lee, Min Kyoung Jo, Jiwan Woo, Yakdol Cho, Dongjoo Lee, Hongyoon Choi, Cherlhyun Jeong, Gi-Hoon Nam, Minsu Kwon, In-San Kim

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008864; DOI: 10.1136/jitc-2024-008864
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species
Man Zhu, Wenjun Tang, Xiaoyu Tang, Zeren Zhu, Yina Jiang, Ammar Sarwar, Hongmei Zhang, Dake Chu, Zixi Zhang, Yanmin Zhang

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009099; DOI: 10.1136/jitc-2024-009099
A crisis in clinical research
David S Hong, Patricia LoRusso, Mario Sznol

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008520; DOI: 10.1136/jitc-2023-008520
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
Juan Chen, Jia-Si Liu, Jun-Yan Liu, Lei She, Ting Zou, Fan Yang, Xiang-Ping Li, Zhan Wang, Zhaoqian Liu

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009399; DOI: 10.1136/jitc-2024-009399
Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3
Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e007766corr1; DOI: 10.1136/jitc-2023-007766corr1
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009595; DOI: 10.1136/jitc-2024-009595
Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma
Yang Chen, Yu Zhou, Ran Ren, Yu Chen, Juan Lei, Yongsheng Li

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008811; DOI: 10.1136/jitc-2024-008811
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids
Elias Burri, Joanna Mangana, Phil F Cheng, Alia Schneider, Achim Weber, Reinhard Dummer, Egle Ramelyte

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008074; DOI: 10.1136/jitc-2023-008074

Main menu

Special collections

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Special collections

Pages